Source:http://linkedlifedata.com/resource/pubmed/id/20002356
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2010-7-13
|
| pubmed:abstractText |
In an open-label, prospective, pharmacokinetic assessment, we evaluated total drug exposure (area under the curve [AUC]) of intravenous (IV) ganciclovir (GCV) and oral (p.o.) valganciclovir when normalized for body surface area (BSA) in pediatric liver (n=20) and renal (n=26) transplant patients Reference doses for IV GCV (200 mg/m(2)) and p.o. valganciclovir (520 mg/m(2)) were based on adult doses, and adjusted for BSA initially, and BSA and renal function (estimated via creatinine clearance [CrCL]) thereafter. Renal transplant patients received GCV on days 1-2, valganciclovir 260 mg/m(2) on day 3, and valganciclovir 520 mg/m(2) on day 4. Liver transplant patients received twice daily GCV from enrollment to day 12, and then valganciclovir twice daily on days 13-14. GCV pharmacokinetics were described using a population pharmacokinetic approach. Type of solid organ transplant (kidney or liver) had no effect on GCV pharmacokinetics. Median GCV exposure following valganciclovir 520 mg/m(2) was similar to that with IV GCV, and to that reported in adults. Patients <5 years of age had AUC values approximately 50% of those compared with older age ranges; dosing based on both BSA and CrCL increased drug exposure in younger patients. A dosing algorithm based on BSA and CrCL should be tested in future studies.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1399-3062
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
12
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
195-203
|
| pubmed:meshHeading |
pubmed-meshheading:20002356-Administration, Oral,
pubmed-meshheading:20002356-Adolescent,
pubmed-meshheading:20002356-Adult,
pubmed-meshheading:20002356-Algorithms,
pubmed-meshheading:20002356-Antiviral Agents,
pubmed-meshheading:20002356-Area Under Curve,
pubmed-meshheading:20002356-Body Surface Area,
pubmed-meshheading:20002356-Child,
pubmed-meshheading:20002356-Child, Preschool,
pubmed-meshheading:20002356-Creatinine,
pubmed-meshheading:20002356-Cytomegalovirus Infections,
pubmed-meshheading:20002356-Dose-Response Relationship, Drug,
pubmed-meshheading:20002356-Female,
pubmed-meshheading:20002356-Ganciclovir,
pubmed-meshheading:20002356-Humans,
pubmed-meshheading:20002356-Infant,
pubmed-meshheading:20002356-Injections, Intravenous,
pubmed-meshheading:20002356-Kidney Transplantation,
pubmed-meshheading:20002356-Liver Transplantation,
pubmed-meshheading:20002356-Male,
pubmed-meshheading:20002356-Young Adult
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.
|
| pubmed:affiliation |
Department of Surgery, Indiana University, Indianapolis, Indiana 46202-5124, USA. mpescov@iupui.edu
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|